phylactic AEDs in the perioperative period to patients who have never had a seizure and who are undergoing brain tumor resection to prevent the adverse effects of a postoperative seizure. Indeed, in a recent survey conducted by Glantz et al., 12 81% of neurosurgeons reported that they prescribed prophylactic AEDs to patients without a history of seizures. Phenytoin is the most commonly administered anticonvulsant, although recently other anticonvulsants, particularly levetiracetam, have been increasingly prescribed.
Temkin et al. 22 studied the efficacy of phenytoin in the prevention of posttraumatic seizures in a prospective, randomized, double-blind study of 404 patients with serious head injuries and found a significant beneficial effect of phenytoin against seizures during the 1st week after head trauma, although continued administration of phenytoin beyond 7 days did not prevent late seizures. This study suggested that 7 days of phenytoin prophylaxis is sufficient to prevent early seizures in this patient population. However, the effect of AEDs in trauma patients may not readily apply to patients undergoing surgery for brain tumors. North et al. 16 performed a randomized study of seizure prophylaxis with phenytoin after supratentorial neurosurgery for a variety of indications in 281 patients, only 45 of whom underwent craniotomy for cerebral metastases or gliomas. The authors observed fewer seizures in the patients given phenytoin prophylaxis, and the most protective effect of the drug was observed in the first 30 days, suggesting efficacy for short-term prophylaxis. However, patients with diagnoses other than brain tumors were included in this study. Two other clinical trials have focused on seizure prophylaxis only in patients with brain tumors, but these studies did not specifically address perioperative prophylaxis. 10, 12 Interestingly, no beneficial effects of seizure prophylaxis were observed in these clinical trials.
Because there is no study that has specifically focused on perioperative seizures in patients with brain tumors, it is currently unclear whether prophylactic, perioperative AEDs should be routinely administered to patients with brain tumors who have never had a seizure and who are undergoing resection of their tumor. Therefore, to evaluate the efficacy and safety of perioperative phenytoin prophylaxis in this patient population, we conducted a prospective, randomized study of patients with gliomas or cerebral metastases randomized to receive or not receive phenytoin for the initial 7-day period following tumor resection.
Methods

Study Design
Eligible patients with either metastatic brain tumors or gliomas based on their preoperative diagnosis as determined either by stereotactic biopsy or MRI were enrolled in the study. Patients were randomized to receive either short-term (7-day) AED prophylaxis with phenytoin (prophylaxis group) or not to receive prophylaxis (observation group). The primary end point was the occurrence of a seizure, and the secondary end point was the occurrence of adverse reactions to phenytoin. Informed consent and institutional review board approval were obtained per the guidelines of The University of Texas MD Anderson Cancer Center.
Eligibility Criteria
Patients with intraparenchymal supratentorial brain tumors either proven by biopsy to be a brain metastasis or a glioma, or with compelling CT or MRI evidence of metastasis or glioma, were selected for this study. All patients had to be previously untreated, with the exception of whole-brain radiation therapy more than 4 weeks prior to enrollment, and all patients had to undergo craniotomy for resection of their brain tumor, with the goal of maximal safe resection of the targeted lesion. All eligible patients also had to have had no seizure on presentation prior to entering the study and not have received any prophylactic AED therapy prior to enrollment. Other inclusion criteria were age 8 years or older, KPS score ≥ 70, and normal electrolyte values (Na, K, Mg, PO 4 , and Ca within 10% of institutional normal) prior to surgery. Exclusion criteria were a history of epilepsy or seizures, solely posterior fossa tumors, the existence of any other past or concomitant intracranial pathology, prior adverse reaction to phenytoin, whole-brain radiation therapy within 4 weeks of enrollment, any previous resection other than stereotactic biopsy, leptomeningeal disease, elevated liver enzymes (aspartate aminotransferase, alanine aminotransferase, and bilirubin ≥ 3 times institutional normal), lactation, and pregnancy (diagnosed by a b-human chorionic gonadotropin level ≥ 5 mIU/ml).
Patient Evaluation and Follow-Up
All patients underwent a pretreatment evaluation including a complete medical history and general physical examination; assessment of seizure and anticonvulsant history; KPS score; neurocognitive assessment; MRI of the brain without and with contrast; and complete blood count, platelet, electrolyte, Ca, Mg, PO 4 , and liver function test measurements. Patients with childbearing potential also had serum b-human chorionic gonadotropin levels measured.
All patients underwent postoperative MRI within 72 hours of surgery. Follow-up evaluations were conducted daily for up to 3 days after surgery while patients were in the hospital and then on postoperative Day 8. Subsequent follow-up was then conducted every 2-3 months up to 12 months. At each follow-up evaluation, history of any new seizures was recorded and serum electrolytes were measured. In addition, at the 8-day and 1-month evaluations, patients randomized to the phenytoin arm were assessed for signs and symptoms of phenytoin toxicity, including nystagmus, blurred vision, ataxia, drowsiness, rash, fever, hirsutism, acne, gingival hyperplasia, hepatosplenomegaly, arthralgia, and eosinophilia, and liver function studies were conducted. Serum phenytoin levels were also measured daily in the morning while patients were in the hospital and on Day 8 of follow-up. Patients with evidence of phenytoin toxicity and normal phenytoin levels also had their albumin levels measured.
Adverse events were recorded and graded on severity using the National Cancer Institute Common Toxicity criteria on a scale from 1 to 5 (1 = mild, 2 = moderate, 3 = severe, 4 = life threatening, and 5 = lethal). Events in Grades 1 or 2 were classified as minor, while events in Grades 3, 4, or 5 were classified as major and corresponded to complications with significant negative impact on patient outcome and/or course of treatment. Each adverse event was reviewed by the primary investigator and was determined to be unrelated, or possibly, probably, or definitely related, to phenytoin treatment.
Phenytoin Administration
Patients randomized to the observation group did not receive any phenytoin before or after surgery until the end of their participation in the study, defined by death, definite seizure, or at the 12-month follow-up evaluation, or if informed consent was withdrawn.
Patients randomized to the prophylaxis group received a loading dose of phenytoin (15 mg/kg intravenously) in the operating room prior to commencing the craniotomy, followed by 100 mg every 8 hours (orally or intravenously) for 7 days postoperatively, and then tapered starting on postoperative Day 8 with a 100-mg dosage decrease every 2 days until discontinuation. Phenytoin levels were obtained immediately after surgery and then daily in the morning while patients were in the hospital. Additional boluses and/or changes in daily dosing were made as needed per the primary physician's judgment, with a therapeutic goal of maintaining phenytoin levels between 10 and 20 mg/L. Serum phenytoin levels were also measured at the Day 8 follow-up.
Seizure Determination
Patients were instructed to contact the study nurse when they had a suspected new seizure. Seizures were diagnosed primarily by clinical manifestations including involuntary movements; alteration in consciousness; or abnormal motor, sensory, or psychosensory phenomena. An independent senior neurologist (A.F.), blinded to the patients' treatment, confirmed the occurrence of every seizure. If a seizure could not be definitely diagnosed on clinical grounds alone, EEG was performed within 24 hours of event occurrence to confirm the diagnosis. If EEG showed evidence of interictal or seizure activity, the event was upgraded to a definite seizure. If EEG was not done within 24 hours or if the EEG findings were not diagnostic, the event was classified as no seizure or possible seizure as determined by the blinded neurologist.
Seizures were classified as early seizures if they occurred within 30 days of surgery. This period of time corresponded to the period of postoperative phenytoin administration, through to the completion of the taper, and including the first 2 weeks following complete cessation of antiepileptic medication. Intraoperative seizures that occurred during direct cortical stimulation due to the application of an electrical current were not considered an end point to the study.
Seizures were classified as clinically significant if the sequelae of the seizure resulted in neurological deficits, hospital admission, or alteration of the patient's course in the hospital, including transfer from the postoperative nursing unit to the ICU, a delay in transfer out of the ICU to the postoperative nursing unit, a delay in transfer from the postoperative nursing unit to inpatient rehabilitation, or a delay in discharge from the hospital.
Serum electrolytes, Ca, Mg, and PO 4 were obtained within 24 hours of every seizure occurrence. Patients taking phenytoin also had determination of serum drug levels and liver function tests. All definite seizures were treated as deemed appropriate by the attending physician and were considered failures of prophylaxis.
Statistical Analysis
Using an estimated seizure incidence of 30% in the observation arm and 10% in the prophylaxis arm and a Type II error of 0.20, a target accrual of 142 patients (71 per arm) was planned. This accrual ensured that our trial would have a power of at least 0.80, as determined by the Fisher exact test, to detect a clinically meaningful twothirds (67%) reduction in the odds of seizure in the phenytoin prophylaxis group (that is, a reduction of seizure incidence from 30% to 10%). Primary analysis was conducted on an intent-to-treat basis. Statistical analysis with the Fisher exact test was performed using SPSS software. A p value < 0.05 was considered statistically significant. Seizure frequency rates for each arm were also compared in an odds ratio analysis. Freedom from seizure curves were generated by the Kaplan-Meier method and were compared using a log-rank test. Perioperative freedom from seizure was defined as the number of days from randomization to the incidence of the first seizure, or to 30 days in the case of seizure-free patients.
Decision to Terminate the Trial
At 6 years when 123 patients had been enrolled, just 19 short of the goal, the trial was closed to further accrual because an interim futility analysis using Bayesian predictive probabilities performed by an independent DSMB demonstrated a low likelihood that either the observation or phenytoin prophylaxis group would be superior if the study were completed to its full sample size (Appendix). At the time of this analysis, 11 seizures had occurred in the observation arm and 15 seizures had occurred in the phenytoin arm. Based on these data, the Bayesian predicted probability was only 0.003 that there would be sufficient evidence at the end of the study to conclude that prophylaxis reduced the rates of seizures compared with observation. In addition, the probability was 0.997 that there would be insufficient evidence at the end of the trial to show that one treatment was superior to the other. In other words, it was extremely unlikely that the proposed difference in seizure rates (that is, reduction from 30% to 10%) would be realized. Therefore, the trial was closed before reaching its planned accrual of 142 patients.
Because the detected incidence of early seizures was only 8% in the control group of our study (significantly less than our estimated rate of 30%), the true power of our study to detect a clinically important difference (twothirds reduction in postsurgical 30-day seizure incidence) based on our accrual of 123 patients was only 19%. It is important to note that the main cause of this limited power was the lower-than-expected incidence of seizures and not poor accrual (we only needed 19 more patients to reach our accrual goal). In fact, with an 8% incidence of early seizures in the control (observation) arm, a Type I error of 5%, and a power of 80%, more than 700 patients would have been needed to detect a two-thirds decrease in seizure rate (from 8% to 3%). To demonstrate smaller reductions of 50%, 40%, or 30% would have required even larger numbers of patients (1204, 2250, and 5306 patients, respectively). This accrual target was not considered feasible and the trial was closed.
Nevertheless, we present the results of the 123 patients entered into this trial because to date this is the first and only clinical trial to focus specifically on perioperative seizure prophylaxis in patients with brain tumors, the cohort is larger than any other prospective study of seizure prophylaxis in brain tumor patients, 10 and the data provide important prospective information about the actual rates of perioperative seizures in patients undergoing craniotomy for brain tumors.
Results
Study Population
Patient enrollment continued from July 17, 2000, to February 24, 2006. A total of 123 patients (77 with metastases and 46 with gliomas) were enrolled and randomized. Sixty-one patients were randomized into the observation group (38 with metastases and 23 with gliomas), and 62 patients were randomized into the prophylaxis group (39 metastases and 23 gliomas).
A comparison of patient characteristics between the treatment groups is summarized in Table 1 . There were no differences between treatment groups in terms of median age, sex, preoperative KPS score, preoperative signs and symptoms, use of direct cortical stimulation mapping, tumor location, tumor size, number of brain lesions or metastases, or extent of resection.
A summary of the histopathological diagnoses is provided in Table 2 . In the metastasis subgroup, tumor types were distributed equally between arms, except that there was a significantly greater incidence of melanoma in the prophylaxis group (36%) than in the observation group (13%, p = 0.03). In the glioma subgroup, 80% of tumors were high-grade gliomas, and 13% were low-grade gliomas. No statistically significant differences in glioma grade or type were observed between treatment groups. Three patients initially included in the glioma subgroup turned out to have a final histopathological diagnosis that was not a glioma. Of these, there was 1 metastasis, 1 lymphoma, and 1 T-cell lymphoproliferative disorder. These 3 cases were kept in the glioma subgroup for subsequent analysis in keeping with the intent-to-treat protocol.
Seizure Incidence
A total of 26 seizures occurred in the patients in this study (Table 3) . Eleven seizures (18%) occurred in the observation group and 15 (24%) occurred in the prophylaxis group. This difference in rates was not statistically significant (p = 0.51). Likewise, no significant difference was observed in the incidence of seizures between the observation and prophylaxis groups in separate analyses of the metastasis (13% vs 15%, p = 1.00) or glioma (26% vs 39%, p = 0.53) subgroups (Table 3) .
Seizures were characterized as generalized, focal, complex partial, or other. There was no difference between treatment groups with regard to the type of seizure in the entire group (p = 0.60) or the metastasis (p = 0.98) or glioma (p = 0.47) subgroups.
A total of 11 patients had early postoperative seizures, that is, within 30 days of surgery, which is the period that encompassed the time of administration and taper of the seizure prophylaxis and the first 2 weeks immediately after cessation of antiepileptic medication. These seizures were likely related to recent resection. Of these early seizures, 5 (8%) occurred in the observation group, and 6 (10%) occurred in the prophylaxis group; this difference was not significant (p = 1.00). One patient (2%) in the prophylaxis group and 2 patients (3%) in the observation group had seizures postoperatively on the day of surgery. Of the phenytoin-treated patients who had early seizures, no seizures were reported during the tapering period (postoperative Days 8-12), but 4 patients had seizures in the period between complete cessation of treatment and 30 days. No significant difference was observed in the incidence of seizures between the treatment groups within the first 24 hours (2% prophylaxis group vs 3% observation group, p = 0.62), 3 days (3% vs 5%, p = 0.68), 1 week (3% vs 8%, p = 0.274) or 30 days (10% vs 8%, p = 1.00) after surgery. The observed odds for an early seizure in the prophylaxis group relative to the observation group was 1.4 (95% CI 0.425-4.763). Therefore, a clinically meaningful reduction (defined as 67% in our trial) in the incidence of seizure was not achieved by treatment with phenytoin compared with no drug.
Because the trial end point was spontaneous seizures in the postoperative period, patients who had intraoperative seizures during electrocortical brain mapping were kept in the trial and were evaluated for subsequent seizures. Of the 34 patients who underwent electrocortical mapping, 2 patients had a focal intraoperative seizure during cortical stimulation. These stimulation-induced seizures were focal motor seizures involving the contralateral extremity/face during stimulation of the motor cortex. Seizure activity stopped within seconds of cold Ringer lactate application over the surface of the stimulated cortex. Both of these patients were in the phenytoin arm and experienced an intraoperative seizure despite therapeutic levels of antiepileptic agents. One of these patients had an early seizure (2 days after surgery), and the other had a late seizure (84 days after surgery). Figure 1 shows the actuarial probability of remaining seizure free in the first 30 days according to treatment group. The prophylaxis group had a mean (± SE) freedom from seizure of 28.4 ± 0.7 days (95% CI 26.9-29.8 days) compared with the observation group, which had a mean freedom from seizure of 27.7 ± 1.0 days (95% CI 25.8-29.6 days). There was no significant difference in freedom from seizure between the groups as a whole (p = 0.80, log-rank test), or in the metastasis (p = 0.53, log-rank test) or glioma (p = 0.48, log-rank test) subgroups. Across both arms and within the metastasis and glioma subgroups, tumors affecting the frontal and temporal lobes were more likely to produce seizures, although this difference was not found to be statistically significant (p = 0.76).
A total of 15 patients had late seizures, that is, seizures that occurred more than 30 days after surgery. Whether these seizures were directly related to the tumor resection/craniotomy was difficult to determine because patients received local (radiation) and systemic (chemotherapy) treatments during this time in the course of their disease and because tumor recurrences are also known to produce seizures. In fact, 5 (36%) of these late seizures were associated with unequivocal tumor recurrence. Nevertheless, no significant difference was observed in the incidence of late seizures between the observation and prophylaxis groups in the entire group, and in separate analyses of the metastasis or glioma subgroups (Table 3) .
A total of 7 clinically significant seizures occurred in the patients in this study, and 3 clinically significant seizures occurred within 30 days and, therefore, were likely due to recent craniotomy. In the first case, a series of generalized seizures occurred over the course of the first few hours immediately after surgery, resulting in increased drowsiness and requiring intubation and transfer to the ICU. In the second case, seizures on the 1st postoperative evening in the ICU resulted in a postictal hemiparesis, with mild residual weakness remaining at the time of discharge 6 days after surgery. In the third case, a seizure occurring 2 days after surgery resulted in mild weakness that delayed discharge by 1 week. Of these clinically significant early seizures, 2 occurred in patients in the observation group, and 1 occurred in the prophylaxis group.
Once again, there were no statistically significant differences in the incidence of clinically significant seizures between the observation and the prophylaxis groups, either in the entire group (3% vs 2%, p = 0.62) or each of the metastasis (3% vs 0%, p = 0.49) or glioma (4% vs 4%, p = 1.00) subgroups (Table 3) .
Serum Phenytoin Levels
Serum phenytoin levels are shown in Table 4 . The loading dose quickly produced therapeutic levels on the day of surgery in 78% of patients, and levels were maintained within target range for the majority of patients (70%-80%) in the study through 3 days after surgery. The percentage of patients for whom blood levels were drawn decreased as patients were discharged from the hospital. Nevertheless, drug levels remained high in the patients for whom phenytoin measurements were available. At the conclusion of the week, levels were considerably lower. This phenomenon was noted by Temkin et al. 22 and may be ascribed to the hypermetabolic state of patients and unpredictable kinetics of phenytoin at 1 week postoperatively, 11 or partial noncompliance after discharge.
Adverse Events
A total of 20 adverse events that were possibly, probably, or definitely related to seizure prophylaxis occurred within 30 days of surgery, which involved 11 patients (12 events in 7 patients in the metastasis subgroup and 8 events in 4 patients in the glioma subgroup). Of these, a total of 5 major adverse events occurred in 3 patients (4 events in 2 patients in the metastasis subgroup, and 1 event in 1 patient in the glioma subgroup). Adverse events included rash and increased liver function test values (4 events each); thrombocytopenia, confusion, and aphasia (2 events each); and decreased level of consciousness, nausea, vomiting, dry itchy skin, ataxia, and photophobia (1 event each). Among the 5 major adverse events, 2 were gastrointestinal and 3 were neurological. A comparison of the number of adverse events within 30 days potentially related to seizure prophylaxis in each treatment group is shown in Table 5 . When all patients were considered, there were significantly more total (18% vs 0%, p < 0.01) and minor (15% vs 0%, p < 0.01) adverse events among the prophylactic group than among the observation group. Differences in the occurrence of major adverse events were not statistically significant but favored the observation group (5% prophylaxis group vs 0% observation group, p = 0.24). In the metastasis group, there were significantly more total adverse events in the prophylaxis group than in the observation group (18% vs 0%, p = 0.01), but no significant difference in the occurrence of major (5% vs 0%, p = 0.49) or minor (13% vs 0%, p = 0.06) adverse events, although more adverse events occurred in the prophylaxis group. In the glioma subgroup, no significant difference was seen in the occurrence of total (17% vs 0%, p = 0.11), major (4% vs 0%, p = 1.00), or minor (17% vs 0%, p = 0.11) adverse events, but again more adverse events occurred in the prophylaxis group.
Discussion
To our knowledge, this study is the first randomized, prospective clinical trial to specifically examine the perioperative use of prophylactic AEDs in patients undergoing resection for brain tumors without a previous history of seizures. Two prior studies examining the use of prophylactic phenytoin after craniotomy showed efficacy of prophylaxis in reducing the incidence of postoperative seizures, but these trials included patients with a variety of neurosurgical problems, including aneurysms and head trauma, in addition to tumors. 16, 17 Two other studies have explored the use of prophylactic AEDs exclusively in brain tumor patients, but most of the patients in these studies did not undergo resection. Glantz et al. 12 conducted a randomized, placebo-controlled trial using divalproex sodium for seizure prophylaxis in 74 patients with newly diagnosed brain tumors, 25 of whom had surgery, and found that prophylaxis was not effective in preventing seizures. Forsyth et al. 10 reported a randomized trial of prophylactic AEDs in 100 newly diagnosed brain tumor patients (60 cerebral metastases and 40 primary brain tumors), 39 of whom had a craniotomy for tumor diagnosis and found no statistically significant difference in seizure incidence and seizure-free survival between patients given AEDs and patients who were observed. This study was terminated early due to lower than expected seizure rates, with the authors reporting that more than 900 patients would have been necessary for a suitably powered study. Sirven et al. 20 conducted a meta-analysis of randomized controlled trials of prophylactic AEDs in brain tumor patients performed between 1996 and 2004 (including the trials of Glantz 12 and Forsyth 10 and their colleagues) using phenytoin, valproic acid, and/or pheno- (18) 1 (7) 0.62
1 (20) 1 (17) 1.00
1 (17) 0 1.00
barbital and found no evidence of benefit at 1 week or 6 months in patients with cerebral metastases, gliomas, or meningiomas. Therefore, prophylactic AEDs have consistently failed to demonstrate efficacy in seizure control in newly diagnosed brain tumor patients without a prior history of seizures. Consistent with these results, the prospective randomized trial presented here suggests that the prophylactic use of phenytoin is not effective in preventing seizures in the postoperative period in patients who had never had a seizure and who underwent resection for supratentorial metastases or gliomas. Specifically, we found no statistically significant differences in seizure incidence or freedom from seizure in patients treated with phenytoin compared with patients who were observed. Furthermore, patients in the prophylaxis group had a statistically significantly higher incidence of drug-related morbidity. However, our data must be interpreted with caution because our trial, like the study of Forsyth et al., 10 was terminated early after interim analyses determined that continued accrual to the goal of 142 patients (19 more than actually accrued) was highly unlikely to demonstrate any statistically significant difference between treatment groups. In other words, even if we accrued all patients to the study, we would not have been able to conclude that prophylactic phenytoin was ineffective in preventing seizures because the actual rates of seizures in the observation group, namely 18% overall and 8% early seizures, were significantly lower than the 30% rate for which the study was powered. In fact, based on an early seizure rate of 8%, more than 700 patients would have been needed to be relatively certain (80% power) of a negative result. Nevertheless, these prospective data are of value because they show that the incidence of seizures in patients undergoing craniotomy for brain tumor is low, only 8% in the first 30 days after surgery and only 3% for clinically significant seizures. In contrast, side effects of phenytoin are high. Therefore, when taken in the context of other Fig. 1 . Kaplan-Meier freedom from seizure probability according to treatment group. According to the log-rank test, there was no significant difference in early perioperative freedom from seizure between the two groups as a whole (A, p = 0.80), or in the metastasis (B, p = 0.53) or glioma (C, p = 0.48) subgroups.
clinical trials, our prospective data raise serious concerns about the routine use of prophylactic phenytoin in patients undergoing craniotomy for brain tumors. Any benefit of prophylactic AEDs in brain tumor patients undergoing resection is likely to be quite small and leads to the question of whether such a small benefit would be clinically important given that the baseline rates of seizures (even without anticonvulsants) are low. In addition, such a small beneficial effect would only be justified if the side effects of the AED were extremely mild and rare. Because no currently available AED fulfills these criteria, we would suggest that future studies should focus on identifying the 8% of patients who are at high risk for seizures so that we can specifically target these patients rather than using a global routine administration of anticonvulsants in all patients.
Most of the patients randomized to the prophylactic arm achieved therapeutic blood levels during the first critical days after surgery, with several troughs within target range during the observation period. Indeed, lack of efficacy of phenytoin in preventing early postoperative seizures in this study could not be explained by inadequate dosing, because the average serum drug levels during the 7-day treatment were within therapeutic range in the majority of patients. Nevertheless, it was our experience that attaining adequate drug levels at the end of the week was difficult, despite optimal dosing and frequent monitoring of serum drug concentrations. This phenomenon has been noted in previous studies. 10, 11, 22 Confounding factors include unpredictable kinetics of phenytoin in the postoperative period, 11 hypermetabolism of surgical patients, 22 and drug interactions with antineoplastic therapy. 3 In addition, our ability to measure the effectiveness of treatment after postoperative Day 3 was limited by difficulties with obtaining phenytoin levels after discharge from the hospital. However, despite these limitations, within the patients randomized to the prophylaxis arm, the median number of therapeutic troughs in patients with early seizures compared with those who did not have a seizure was not statistically significant. Ultimately, these issues are relevant to the real-world application of perioperative prophylaxis. It may be that 19%-50% of patients with confirmed epilepsy have subtherapeutic levels.
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The effectiveness of phenytoin prophylaxis in controlling early seizures in patients with head trauma has been demonstrated in a randomized, double-blinded placebo controlled trial. 22 Our findings suggest that this result cannot be generalized to the brain tumor population undergoing craniotomy for resection. Therefore, the assumption that the trauma associated with craniotomy and tumor resection may increase the risk of seizures in a manner analogous to that observed in traumatic head injury does not appear to be supported by the available evidence. A possible explanation for this observation is that in contrast to the situation in head-injured patients where the trauma is uncontrolled, the trauma associated with resection of a tumor occurs in highly controlled circumstances, with the prior administration of general anesthesia and corticosteroids and with minimal local brain manipulation such that secondary injury and kindling of epileptogenic foci are ameliorated. In this context, the causes of seizures in brain tumor patients may well be more related to the effects of the tumor mass and its associated features, such as infiltration of surrounding normal brain, disruption of the bloodbrain barrier, and edema. Resection would be expected to reduce the severity of all these factors. Indeed, seizures associated with specific mass lesions are frequently refractory to control by AEDs and often respond best to resection 0%  0%  2%  0%  0%  17%  0%  56%  5-10  15%  11%  6%  21%  18%  12%  17%  0%  18%  10-20 †  78%  84%  82%  77%  82%  88%  66%  100%  26%  20-30  2%  5%  12%  0%  0%  0%  0%  0%  0% * POD = postoperative day. † Therapeutic drug level. of the epileptogenic focus, a fact that may explain the lack of efficacy of prophylactic AEDs in the setting of brain tumors. It is possible that the most effective means of seizure control in this patient population is the actual resection of the tumor itself. 9, 11 In the large retrospective study by Chaichana et al., 6 of the 24% of patients who presented with seizures, 77% were seizure free 12 months after resection, and 95% had at least meaningful improvement in seizure control after 12 months.
A major risk of intraoperative cortical mapping is stimulation-induced seizures. Consequently, neurosurgeons may administer prophylactic AEDs in patients undergoing electrocortical stimulation to prevent an intraoperative seizure during mapping. However, despite therapeutic levels of antiepileptic agents, intraoperative stimulation-evoked seizures may occur in up to 5%-20% of patients. 19 Several retrospective studies have reported rapid and reliable termination of intraoperative seizures with cold Ringer lactate, without any postoperative deficits or increased seizure frequency. 18, 21 This technique is commonly used at our institution and many others. There is little evidence that prophylactic AEDs are effective in the prevention of intraoperative seizures. Therefore, given the side-effect profile of AEDs and the success of cold Ringer lactate in terminating stimulation-evoked seizures with minimal morbidity, antiepileptic prophylaxis for patients undergoing cortical stimulation may not be warranted. Only a randomized controlled trial on the use of prophylactic AEDs for seizure prophylaxis in brain tumor patients undergoing resection with cortical stimulation mapping would definitively answer this question.
We suspect that our results with phenytoin are generally applicable to all AEDs. In particular, levetiracetam recently has become a popular alternative to phenytoin for seizure prophylaxis due to a possibly more favorable side effect profile and a lack of drug interactions.
15 A Phase II study with a small number of patients suggested that the use of levetiracetam for seizure prophylaxis in brain tumor patients is safe and equally effective compared with phenytoin. 15 A more favorable side-effect profile could shift the balance of risk versus benefit in favor of use of prophylactic AEDs. However, in light of our results, equally effective compared with phenytoin begs the question of whether phenytoin, or any prophylactic AED, offers any clinically meaningful benefit at all in the brain tumor population. This is a question that can only be answered definitively with a randomized controlled trial of the use of levetiracetam for seizure prophylaxis in brain tumor patients undergoing resection. However, we are not aware that such a study has yet been attempted.
Conclusions
There is no consensus among neurosurgeons treating patients with brain tumors regarding the use of perioperative prophylactic AEDs. The low rates of seizures seen in the control arm of this prospective trial raise serious concerns that the routine use of perioperative prophylactic phenytoin in patients with brain tumors may not be warranted.
Appendix
Use of Bayesian Predictive Probabilities to Monitor Patient Enrollment
Bayesian predictive probabilities can be used to monitor randomized clinical trials to assess the likelihood based on current data that the study will ultimately conclude that either one or the other of the treatments is superior or that there will be insufficient evidence at the end of the trial to draw a conclusion. 2, 8 We conducted a binary end point randomized clinical trial with 2 arms: Arm A (no prophylaxis) and Arm B (short-term prophylaxis). The primary end point was occurrence of the first definitive seizure. The initial sample size calculation indicated that we needed 71 patients per arm for a total of 142 patients (using the standard 2-sample test for proportions). At the final DSMB review a total of 123 patients had been randomized. Sixty-one patients had been randomized to Group A and 62 to Group B.
Let q A and q B be the probabilities of seizure in Arms A and B, respectively. At the final DSMB review, there had been 11 seizures in Arm A and 15 in Arm B. To compute the predictive probabilities, we examined all possible pairs of outcomes for future patients, computing and summing up the individual event probabilities. Based on the data at the time of the final DSMB review, the probability that we would conclude at the end of the study that Arm A had a higher event probability than Arm B (that is, q A > q B ) was < 0.001 and the probability that we would conclude that Arm B had a higher event probability than A (that is, q B > q A ) was 0.003. The probability that there would be insufficient evidence at the end of the trial to choose either Arm A or B as superior was 0.997.
Methods
Suppose we are conducting a binary end point randomized clinical trial with 2 arms, Arms A and B. Let q A and q B be the probabilities of response in Arms A and B, respectively. We can perform an interim analysis using Bayesian predictive probabilities to calculate the probability that, given the current data, at the end of the trial we will conclude q A > q B or q B > q A (or the probability that there will be insufficient evidence at the end of the trial to choose either Arm A or B). This last outcome allows us to stop a study early if it is unlikely that the study will reach a meaningful conclusion.
Let X A be the number of patients with events observed to date on Arm A, m A the total number of patients observed to date on Arm A, Y A a hypothetical number of future successes on arm A, and N A the total number of patients who will be treated on Arm A. Further, let n A = N A -m A be the number of hypothetical future patients to be treated on Arm A. Denote the analogous quantities for Arm B similarly.
We assume a priori that q A and q B are independently distributed as beta(a,b) and that X A | q A ~ binomial(q A , m A ) and that X B | q B ~ binomial(q B , m B ). The assumptions imply that, a posteriori, q A | X A ~ beta(a + X A , b + m A -X A ) and q B | X B ~ beta(a + X B , b + m B -X B ). Note that there are m A -X A patients without events observed to date in Arm A and m B -X B patients without events observed to date in Arm B.
The posterior predictive probability of Y A = y patients with events in the future given X A patients with events observed to date is Pr(Y A = y|X A ) = where B(a,b) denotes the beta function. 8, 23 The posterior predictive probability for Arm B is similarly calculated. 
Software
User-friendly software to compute predictive probabilities for monitoring trials can be downloaded. 23 The software also provides for monitoring trials with time-to-event end points and trials with frequentist designs (to compute the interim probability of the design criteria ultimately being satisfied). Furthermore, the software provides for designing trials based on predictive probabilities. A program for computing Pr(q A > q B ) given the parameters of the 2 distributions is included or can be downloaded separately under the name "Inequality Calculator."
